Use of Inhaled Nitric Oxide
- 1 August 2000
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 106 (2) , 344-345
- https://doi.org/10.1542/peds.106.2.344
Abstract
Approval of inhaled nitric oxide by the US Food and Drug Administration for hypoxic respiratory failure of the term and near-term newborn provides an important new therapy for this serious condition. This statement addresses the conditions under which inhaled nitric oxide should be administered to the neonate with hypoxic respiratory failure.Keywords
This publication has 19 references indexed in Scilit:
- Inhaled nitric oxide in term and near-term infants: Neurodevelopmental follow-up of The Neonatal Inhaled Nitric Oxide Study Group (NINOS)The Journal of Pediatrics, 2000
- Low-Dose Nitric Oxide Therapy for Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 2000
- Safety of Withdrawing Inhaled Nitric Oxide Therapy in Persistent Pulmonary Hypertension of the NewbornPublished by American Academy of Pediatrics (AAP) ,1999
- Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter StudyPediatrics, 1998
- Inhaled Nitric Oxide and Hypoxic Respiratory Failure in Infants With Congenital Diaphragmatic HerniaPediatrics, 1997
- Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 1997
- Inhaled Nitric Oxide in Full-Term and Nearly Full-Term Infants with Hypoxic Respiratory FailureNew England Journal of Medicine, 1997
- Inhaled nitric oxide in term infants with hypoxemic respiratory failureThe Journal of Pediatrics, 1996
- Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.Circulation, 1991
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987